Lake Street raised the firm’s price target on Stereotaxis to $4 from $3 and keeps a Buy rating on the shares. While calling the company’s Q4 report “mixed,” the firm thinks the value of positive regulatory achievements and expected new product launches in 2024 will outweigh the miss due to system revenue recognition variability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STXS:
- Stereotaxis Reports 2023 Full Year Financial Results
- Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
- STXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology
- Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
